Gain Therapeutics, Inc. (GANX)
1.79
-0.04
(-2.19%)
USD |
NASDAQ |
Sep 09, 13:20
Gain Therapeutics Debt to Equity Ratio : 0.054 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.054 |
| March 31, 2026 | 0.048 |
| December 31, 2025 | 0.0394 |
| September 30, 2025 | 0.1024 |
| June 30, 2025 | 0.1841 |
| March 31, 2025 | 0.105 |
| December 31, 2024 | 0.089 |
| September 30, 2024 | 0.0864 |
| June 30, 2024 | 0.0685 |
| March 31, 2024 | 0.1029 |
| December 31, 2023 | 0.0817 |
| September 30, 2023 | 0.1417 |
| June 30, 2023 | 0.1031 |
| Date | Value |
|---|---|
| March 31, 2023 | 0.0797 |
| December 31, 2022 | 0.0675 |
| September 30, 2022 | 0.056 |
| June 30, 2022 | 0.0513 |
| March 31, 2022 | 0.047 |
| December 31, 2021 | 0.0462 |
| September 30, 2021 | 0.0387 |
| June 30, 2021 | 0.0368 |
| March 31, 2021 | 0.0275 |
| December 31, 2020 | 0.2034 |
| September 30, 2020 | 0.1062 |
| December 31, 2019 | -0.4468 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
| Vericel Corp. | 0.2556 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 15.42M |
| Total Liabilities (Quarterly) | 4.130M |
| Shareholders Equity (Quarterly) | 11.29M |
| Current Ratio | 4.359 |
| Net Debt Paydown Yield | 0.00% |